原发性硬化性胆管炎及其一级亲属中的自身免疫性疾病
这项匹配队列研究纳入1378例原发性硬化性胆管炎(PSC)患者、13549名一般人群对照及其一级亲属,评估自身免疫病的共病与家族关联及其对严重结局的影响。PSC患者非IBD、非自身免疫性肝炎的自身免疫病患病率为18%,对照为11%(OR 1.77);PSC患者一级亲属的IBD、自身免疫性肝炎及任何自身免疫病发生 odds 均高于对照亲属。PSC患者的自身免疫共病与严重结局无关(HR 0.96)。
要点
- PSC患者自身免疫病患病率18%,对照11%,OR 1.77(95% CI 1.53-2.05)。
- PSC患者一级亲属的IBD、自身免疫性肝炎及任何自身免疫病 odds 均高于对照亲属。
- PSC患者的自身免疫共病与严重结局无关(HR 0.96,95% CI 0.71-1.28)。
核心结论
- PSC患者及其一级亲属患自身免疫病的 odds 高于匹配对照,这一发现在表型层面验证了此前的遗传学发现;自身免疫共病未影响严重结局。
研究设计与样本
- 匹配队列研究,纳入1378例PSC患者、13549名一般人群对照及其一级亲属;由国家登记系统提供诊断与结局(肝移植、肝胆癌、肝病相关死亡)数据。
主要发现
- PSC患者非IBD、非自身免疫性肝炎的自身免疫病患病率为18%,对照为11%,OR 1.77(95% CI 1.53-2.05)。
- 乳糜泻 OR 4.36(95% CI 2.44-7.49),结节病 OR 2.74(95% CI 1.29-5.33),1型糖尿病 OR 2.91(95% CI 2.05-4.05),自身免疫性皮肤病 OR 2.15(95% CI 1.52-2.96)。
- PSC患者一级亲属患IBD的 OR 为3.25(95% CI 2.68-3.91),患自身免疫性肝炎的 OR 为5.94(95% CI 2.82-12.02),患任何自身免疫病的 OR 为1.34(95% CI 1.19-1.50),均高于对照亲属。
- PSC患者的自身免疫共病与严重结局无关,HR 0.96(95% CI 0.71-1.28)。
关键数值与推荐
- 自身免疫病 odds 采用逻辑回归估计,严重结局 HR 采用Fine和Gray竞争风险回归估计。
- 自身免疫病包括非IBD、非自身免疫性肝炎的自身免疫病,PSC患者患病率18%,对照11%。
- 严重结局包括肝移植、肝胆癌和肝病相关死亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Primary sclerosing cholangitis (PSC) is linked to inflammatory bowel disease (IBD). However, there is limited overlap between IBD and PSC risk genes, but a stronger association between PSC and other autoimmune conditions. We aimed to assess the coexistence and familial association of autoimmune disorders in PSC, and the influence of autoimmune comorbidity on severe outcomes. APPROACH AND RESULTS: In a matched cohort study, 1378 individuals with PSC and 13,549 general population comparators and their first-degree relatives were evaluated. National registries provided data on diagnoses and outcomes (liver transplantation, hepatobiliary cancer, and liver-related death). The OR of autoimmune disease was estimated by logistic regression. The Fine and Gray competing risk regression estimated HRs for severe outcomes. The prevalence of non-IBD, non-autoimmune hepatitis, and autoimmune disease was 18% in PSC and 11% in comparators, OR: 1.77 (95% CI: 1.53-2.05). Highest odds were seen for celiac disease [OR: 4.36 (95% CI: 2.44-7.49)], sarcoidosis [OR: 2.74 (95% CI: 1.29-5.33)], diabetes type 1 [OR: 2.91 (95% CI: 2.05-4.05)], and autoimmune skin disease [OR: 2.15 (95% CI: 1.52-2.96)]. First-degree relatives of individuals with PSC had higher odds of developing IBD, autoimmune hepatitis, and any autoimmune disease than relatives of the comparators [OR: 3.25 (95% CI: 2.68-3.91); OR: 5.94 (95% CI: 2.82-12.02); OR: 1.34 (95% CI: 1.19-1.50)]. Autoimmune comorbidity in PSC was not associated with poorer outcomes [HR: 0.96 (95% CI: 0.71-1.28)]. CONCLUSIONS: Individuals with PSC and their first-degree relatives had higher odds of autoimmune disease compared to matched comparators. This finding provides validation for prior genetic discoveries at a phenotypic level. Autoimmune comorbidity did not impact severe outcomes.
引用
- Lundberg Båve A, von Seth E, Ingre M, et al. Autoimmune diseases in primary sclerosing cholangitis and their first-degree relatives. Hepatology. 2024. PMID: 38441983. doi:10.1097/HEP.0000000000000823
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。